MXPA00005251A - Revitalisation formulation - Google Patents

Abstract

This invention relates to a formulation combining the additive effects of branched chain amino acids, maltodextrins, and salts for manufacture in the food industry for the purpose of reducing:1) Alcohol induced decline in well-being, and/or 2) Appetite for alcohol.

Description

FORMATION OF REVITALIZATION This invention relates to a formulation that combines the additive effects of branched chain amino acids, maltodextrins and salts for manufacturing in the food industry for the purpose of reducing: 1. Decay induced by alcohol in the well-being, and / or 2. Appetite for alcohol. 1 . Alcohol-induced decay in well-being and / or hangover Currently, there is no effective product available for the prevention and / or improvement of alcohol-induced decay in well-being / hangover that does not contain analgesics. The consumption of alcohol causes damage to the liver. The combined ingestion of alcohol and analgesics exacerbates damage to the liver, but this and other detrimental effects of this course of treatment may be masked by analgesia. The present invention prevents or substantially reduces the detrimental effects in the short term of excess alcohol consumption when taken during or after consumption of alcohol, just before sleeping. The invention applies only branched-chain amino acids (BCAAs), maltodextrins (a heterogeneous mixture of mainly long-chain sugars) and salts that act in convention. When used for the prevention and / or improvement of alcohol-induced hangover, unexpectedly BCAAs (which are taken up by the liver [British Medical Bulletin, 48, No. 3, pp 477-495] and mitigate fatigue induced by the serotonin production) are highly effective in solving this problem in combination with maltodextrins (which act to protect amino acids during their passage through the stomach), plus salts (which allow a rapid dispersion in water). This is not obvious: the accepted opinion is that the hangover induced by alcohol is caused mainly by the balance of water, hyperglycemia and irritation of the pia mater by tannins and other co-genera found in alcoholic beverages. 2. Suppression of the appetite for alcohol The consumption of the formulation in water periodically, for example, three times a day, is effective to separate alcohol from alcoholics.

Current treatments focus on blocking endorphins, GABA receptors and / or eye squinting pressure. This is the first effective, non-pharmaceutical, completely food-grade solution for this problem. According to a first aspect, the present invention provides an aqueous solution typically of 250-300 ml in volume containing: a) Maltodextrin, preferably 4 to 1 5 equivalents of dextrose (DE), more preferably 8 to 1 2 DE, at 3 to 10% (w / v), even more preferably at 4 to 6% (w / v) and most preferably at 4.5% (P / v); b) Maltodextrin, preferably at 10 to 75 equivalents of dextrose (DE), more preferably at 10 to 20 DE, most preferably 1 3 to 1 DE, at 0.1 to 2% (w / v), but most preferably at 0.1 5% (w / v); c) Maltodextrin preferably at 6 equivalents of dextrose (DE) at 1 to 10% (w / v), but most preferably at 4% (w / v); d) L-leucine at 0.025 to 5 grams in total, more preferably 0. 025 to 0.75 g in total and most preferably 0.05 g in total; e) L-isoleucine at 0.001 to 5 grams in total, more preferably 0.01 to 0.75 g in total and most preferably 0.025 g in total; f) L-valine at 0.001 to 5 grams in total, more preferably 0.01 to 0.75 g in total and most preferably 0.025 g in total; g) Preferably L-ascorbic acid to about 0.1 g in total; h) Preferably anhydrous citric acid at about 0.4 g; i) Optionally sodium bicarbonate at approximately 0.3 g.

In addition, any colorant, preservative and / or flavoring required, and / or carbonation agent can be used for flavor and / or attraction. In a second aspect, the invention provides an aqueous solution typically of 250-300 ml in volume, containing: a) about 6% (w / v) maltodextrins - formed of 50% MD6, 25% MD 1 0 and 25% MD20; b) approximately 25 mg each of valine and isoleucine; c) approximately 50 mg of leucine; d) about 60 mg of ascorbic acid; and e) about 400 mg of citric acid. In a third aspect, the invention provides dry formulations which, when dissolved in approximately 250-300 ml of liquid, such as water, provide the solutions described above. The dry formulation may optionally contain a sweetening agent, such as Aspartame. The metabolic cleavage of Aspartame when the dissolved formulation is ingested, has the effect of releasing a small amount of methanol in vivo, which improves the efficacy of the product. A preferred amount of Aspartame is about 50 mg. A formulation according to the invention would normally be prepared in a dry form suitable for consumption as a water-based beverage, by a combination with the appropriate amount of water. Advantageously, the preparation may contain a substance that causes effervescence in contact with water: advantageously, the action of effervescence may not only disperse the formulation in the water but also cause a level of solubilization. One form of the formulation can be made from dry components by mixing, and does not require spray drying. It will be apparent to those skilled in the art that prepration in dry form could be mixed with any other liquid, preferably a water-based liquid, for consumption. It is anticipated that the dry preparation could be mixed not only with non-alcoholic liquids, but also with alcoholic liquids, such as beer. Additionally, it will be apparent to those skilled in the art that the formulation can be consumed as a liquid formulation already prepared. In addition, it is anticipated that the formulation could be incorporated into other "carriers" 7 an example would be the preparation of a confectionery article containing the formulation, which could be ingested, while the above description refers both to an alcohol-induced decay in welfare (hangover) and appetite suppression by alcohol, the formulations according to the present invention, can be used in the prevention or amelioration of other symptoms, such as, by way of non-limiting example, metabolic dysfunction, tension, PMS, etc. In In particular, the formulation according to the invention may be useful in the prevention or amelioration of symptoms associated with the release of serotonin by regulation, suppression or prevention of serotonin production It will be apparent to those skilled in the art that the formulation of the present invention could be co-administered with one or more different components, having serotonin-controlling activity (eg, Prozac) and that the BCCA content of the formulation of the present invention could, under appropriate circumstances, be partially or completely substituted with other pharmacologically or physiologically active analogues, such as, for example, Prozac. The formulation of the invention is not only intended for human use, but is also intended to be advantageously administered to animals, in particular in order to prevent or ameliorate the adverse effects of strain on animals. In particular, it is anticipated that the formulation of the invention could be fed to animals prior to slaughter (e.g., pigs), in order to reduce or overcome stress-related problems known to those skilled in the art. The choice of maltodextrin used in the formulation according to the invention is not absolutely critical but, as previously illustrated, a preferred formulation can utilize three maltodextrins (a), (b) and (c) above. It is evident that the DE values referred to above can overlap: those skilled in the art will understand that a choice of maltodextrin could be made within each of the ranges of given values (a) and (b) and that the DE value given in (c) ) falls within the range defined in (a). Nevertheless, as a general guideline, it is preferred to have at least one maltodextrin of DE value below about 10 and a maltodextrin of DE value above 10. The DE value has the effect of the uptake and utilization ratio of maltodextrin by the consumer of the formulation. It will also be apparent to those skilled in the art that some or all of the maltodextrin content of the formulation of the invention could be replaced by different monomers, oligomers and different carbohydrate polymers. However, maltodextrin is preferred because it does not elicit a glycemic response. However, it is anticipated that other carbohydrates could be used according to the invention. Where legally permissible, the present invention provides a method of treatment, prevention or improvement of alcohol-induced hangover or decay in welfare, said method comprising administration of a formulation as described above. The invention also provides a method of appetite suppression for alcohol, said method comprising the administration of a formulation as described above.

Claims (18)

1. CLAIMS 1 . A liquid preparation containing in a liquid volume of 250-300 ml, the following constituents: a) Maltodextrin, preferably 4 to 1 5 equivalents of dextrose (DE), more preferably at 8 to 12 DE, at 3 to 10% (w / v), still more preferably at 4 to 6% (w / v) and preferably at 4.5% (p / v); b) Maltodextrin, preferably at 1 0 to 75 equivalents of dextrose (DE), more preferably at 10 to 20 DE, most preferably 1 3 to 1 DE, at 0.1 to 2% (w / v), but most preferably at 0.1 5% (P / v); c) Maltodextrin preferably at 6 equivalents of dextrose (DE) at 1 to 10% (w / v), but most preferably at 4% (w / v); d) L-leucine at 0.025 to 5 grams in total, more preferably 0.025 to 0.75 g in total and most preferably 0.05 g in total; e) L-isoleucine at 0.001 to 5 grams in total, more preferably 0.01 to 0.75 g in total and most preferably 0.025 g in total; f) L-valine at 0.001 to 5 grams in total, more preferably 0.01 to 0.75 g in total and most preferably 0.025 g in total; g) Preferably L-ascorbic acid to about 0.1 g in total; h) Preferably anhydrous citric acid at about 0.4 g; i) Optionally sodium bicarbonate at approximately 0.3 g.
2. 2. A preparation according to claim 1, containing in a liquid volume of 250-300 ml, the following constituents: a) about 6% (w / v) of maltodextrins - formed of 50% or MD6, 25% MD1 0 and 25 % MD20; b) approximately 25 mg each of valine and isoleucine; c) approximately 50 mg of leucine; d) about 60 mg of ascorbic acid; and e) about 400 mg of citric acid.
3. 3. A preparation according to claim 1 or 2, which is an aqueous solution of the constituents.
4. 4. A preparation according to claim 1 or 2 in the form of an emulsion.
5. 5. A preparation according to claim 1, 2, 3 or 4 further containing a sweetener / colorant / flavoring / preservative and / or carbonation agent.
6. 6. A preparation according to claim 5 which contains about 50 mg of Aspartame.
7. 7. A preparation according to any preceding claim, wherein the maltodextrins are partially or completely replaced with longer or shorter polymer maltodextrins.
8. A preparation according to any preceding claim, wherein the maltodextrins have been partially or completely replaced with a different carbohydrate monomer, oligomer or polymer that does not cause the secretion of insulin.
9. 9. A preparation according to any preceding claim, wherein the BCAAs are replaced in part or completely with their pharmacologically or physiologically active analogues. 1 0.
10. A dry formulation which, when dissolved or suspended in approximately 250-300 ml of liquid, provides a preparation according to any preceding claim. eleven .
11. A dry formulation according to claim 10 in powder form.
12. 12. A dry formulation according to claim 10 in the form of particles. 3.
13. A method for making a dry formulation according to claim 11, which comprises mixing said dry constituents.
14. 14. A method for making a dry formulation according to claim 12, which comprises mixing said dry constituents in the form of particles.
15. The use of a preparation or formulation according to any of claims 1 to 12 in a method for treatment / prevention / amelioration of alcohol-induced hangover and / or alcohol induced decay in well-being.
16. The use of a preparation or formulation according to any of claims 1 to 1 2 in a method for the suppression of alcoholic appetite.
17. 17. A method of treatment / prevention / amelioration of alcohol-induced hangover and / or alcohol-induced decay in welfare, which comprises the administration of a preparation according to any of claims 1 to 9.
18. 18. A method of suppression of alcoholic appetite, which comprises the administration of a preparation according to any of claims 1 to 9. (54) Title: REVITALIZATION FORMULATION (57) Summary: This invention relates to a formulation that combines the additive effects of branched chain amino acids, maltodextrins and salts for manufacturing in the food industry, in order to reduce: 1) alcohol-induced decay, and / or 2) alcohol appetite .